NCT03241186View on ClinicalTrials.gov

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 12, 2017

Primary Completion Date

September 15, 2022

Study Completion Date

September 30, 2023

Conditions
Mucosal Melanoma
Interventions
DRUG

Ipilimumab

1mg/kg

DRUG

Nivolumab

3mg/kg

DRUG

Nivolumab

480mg

Trial Locations (7)

19111

Fox Chase Cancer Center, Philadelphia

32224

Mayo Clinic- Florida, Jacksonville

52242

University of Iowa Hospital and Clinics, Iowa City

55905

Mayo Clinic Rochester, Rochester

68130

Nebraska Cancer Specialists, Omaha

97213

Providence Portland Medical Center, Portland

555455455

University of Minnesota, Minneapolis

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Hoosier Cancer Research Network

OTHER

lead

Robert R. McWilliams, MD

OTHER